DRUG DELIVERY STRATEGIES FOR CROSSING THE BLOOD-BRAIN BARRIER

The brain's gradual neuronal degeneration and disruption of synaptic
transmission are caused by these pathological alterations [1][3].The blood–brain
barrier (BBB), a highly selective biological barrier that shields the brain from
dangerous substances flowing in the bloodstream, is one of the main obstacles to
treating Alzheimer's disease. The BBB restricts the delivery of therapeutic
medicines to the central nervous system even though it is essential for preserving
brain homeostasis. Poor therapy outcomes for neurological illnesses are caused
by many conventional medications' inability to effectively pass the blood-brain
barrier [3][4].Recent developments in nanotechnology have presented medication
delivery methods based on nanoparticles as viable ways to get around these
limitations.